This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

This is a video synopsis/summary of an OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.

Kuhlman detailed common ocular toxicities with FGFR inhibitors such as floaters, flashing lights, and dry eyes. Unfortunately, mitigation is difficult beyond lubricants for dryness, she noted. At symptom onset, patients should schedule an ophthalmology evaluation and potentially start drug holds. Exams every 2 to 3 months should be monitored for issues such as asymptomatic retinal fluid.

Dr Kelley highlighted another potential toxicity: corneal abrasions that require regular lash epilation.

Ms. Bishop, having experienced floaters, retinal fluid, and significant dry eye, affirmed the importance of baseline and serial ophthalmic exams, which provided reassurance when abnormalities arose. Though her issues affected her quality of life, they resolved without intervention.

In conclusion, FGFR inhibitors’ ocular effects range from annoying to medically concerning but are usually low grade. However, thorough patient education and serial ophthalmology assessments are vital for early intervention if significant toxicity threatens vision.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.